Misdiagnosis of Treatable Stroke Mimic: The Case for HIV Screening in Practice Guidelines
Neurohosp 3:125-130, Finelli, P.F., 2013
Brain Biopsy in Patients with Acquired Immunodeficiency Syndrome, Diagnostic Value, Clinical Performance, and Survival Time
Arch Int Med 159:2590-2596, Hornef,M.W.,et al, 1999
Evaluation and Management of Intracranial Mass Lesions in AIDS
Rpt of Quality Stnds Subcomm of the AAN, Neurol 50:21-261998., , 1998
Anal Carcinoma
NCCN.org April 2017 V2.2017, , 2017
Opt-Out HIV Testing in Adult Critical Care Units
Lancet 383:1460, Thornhill, J.,et al, 2014
HIV Testing and Management of Newly Diagnosed HIV
BMJ 349:g4275, Rayment, M.,et al, 2014
Combination Antifungal Therapy for Cryptococcal Meningitis
NEJM 368:1291-1302, Day, J.,et al, 2013
Evidence-based Guideline: Antiepileptic Drug Selection for People with HIV/AIDS
Neurol 78:139-145, Birbeck,G.L.,et al, 2012
Multiple Ring-Enhancing Lesions of the Brain
J Postgrad Med 56:307-316, Garg, R.K. & Sinha, M.K., 2010
Autoimmune Encephalitides: A Broadening Field of Treatable Conditions
Neurologist 22:1-13, Kalman, B., 2017
The Management of Suspected Encephalitis
BMJ 344:e3489, Thwaites, G.E., 2012
The Management of Encephalitis: Clinical Practice Guidelines by the Infectious Disease Society of America
Clinical Infectious Diseases 47:303-327, Tunkel, A.R.,et al, 2008
What All Physicians Need to Know About the Polio Resurgence in New York State
JAMA online e1-e3, Larkin, H., 2022
Preparing a Neurology Department for SARS-CoV-2 (COVID-19)
Neurol 94:886-891, Waldman, G.,et al, 2020
Mechanical Thrombectomy in the Era of the COVID-19 Pandemic: Emergency Preparedness for Neuroscience Teams
Stroke 51:1896-1901, Nguyen, T.N.,et al, 2020
Anosmia and Loss of Smell in the Era of COVID-19
BMJ 370:m2808, Walker, A.,et al, 2020
Myasthenia Gravis
NEJM 375:2570-2581, Gilhus, N.E.,et al, 2016
Evidence-Based Guideline Update: Plasmapheresis in Neurologic Disorders: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurol 76:294-300, Cortese,I.,et al, 2011
Optic Neuritis: Prognosis and Treatment
UpToDate, Jan, Osborne, B.,et al, 2011
Natalizumab and Progressive Multifocal Leukoencephalopathy: What are the Causal Factors and Can It be Avoided?
Arch Neurol 67:923-930, Warnke,C., et al, 2010
Pregnancy and Fetal Outcomes After Interferon-b Exposure in Multiple Sclerosis
Neurol 75:1794-1802, Amato,M.P.,et al, 2010
Genetic Aspects of Alzheimer Disease
The Neurologist 15:80-86, Williamson,J.,et al, 2009
Practice Parameter: Evaluation of the Child with Microcephaly (An Evidence-Based Review): Report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society
Neurol 73:887-897, Ashwal,S.,et al, 2009
Best Practice Recommendations for the Selection and Management of Patients with Multiple Sclerosis Receiving Natalizumab Therapy
Mutliple Sclerosis 15:S26-S36, Coyle,P.K.,et al, 2009
Steroid and Antiviral Treatment for Bells Palsy
Lancet 371:1818-1820, Hato,N.,et al, 2008
Neutralizing Antibodies to Interferon Beta: Assessment of Their Clinical and Radiographic Impact: An Evidence Report
Neurol 68:977-984, Goodin,D.S.,et al, 2007
Neutralizing Anti-IFN-B Antibodies
Neurol 65:6-8, Giovannoni,G.&Goodman,A., 2005
Bell's Palsy
NEJM 351:1323-1331, Gilden,D.H., 2004
Disease Modifying Therapies in Multiple Sclerosis
Neurol 58:169-178, Goodin,D.S.,et al, 2002
Optic Pathway Gliomas in Children with Neurofibromatosis 1:Consensus Stmt NF1 Optic Pathway Glioma Task Force
Ann Neurol 41:143-149, Listernick,R.,et al, 1997
Guidelines for Physicians with Patients on IFNB-1b:The Use of an Assay for Neutralizing Antibodies (NAB)
Neurol 47:865-866, Paty,D.,et al, 1996
Interferon Beta in Multiple Sclerosis
BMJ 313:1159, 1157, 1195996., Richards,R.G., 1996
Practice Advisory on Selection of Patients with Multiple Sclerosis for Treatment with Betaseron
Neurol 44:1537-1540, Alter,M.,et al, 1994